In the Winter 2012 issue of the Journal, the following two statements should have appeared in this article.
PROCESS STATEMENT
The concept of the position paper was developed by AMMI members participating in a Toronto Academic Health Sciences Network pandemic task force working group on health care worker immunization (KK, AM and MV). The concept was approved by the Guidelines Committee of AMMI Canada. The literature review and first draft were developed by KK, AM and MV; all other authors reviewed, revised and approved the document before submission to AMMI Canada. The Guidelines Committee reviewed and provided feedback, followed by approval in April 2012. The Council of AMMI Canada reviewed the draft, requested revisions and then ratified the final document as the official position of AMMI Canada October 14, 2012 (with 11 of 12 Members of Council voting in favour and with one abstention). Following adoption by Council, it was submitted to the Journal for publication.
REAL OR POTENTIAL CONFLICTS OF INTEREST IN THE PAST FIVE YEARS
AM has received research funding from, or been a member of the advisory board of GlaxoSmithKline Inc, Novartis and Sanofi-Pasteur. VR has participated in clinical trials funded by Roche, Schering-Plough, Basilea Pharmaceutica and BioCryst Pharmaceuticals. JE has participated in clinical trials funded by Sanofi Pasteur and Dynavax Technologies. Members of AMMI Canada Council report the following potential conflicts of interest: MR has been a member of the speaker’s bureau of GlaxoSmithKline Inc, in areas unrelated to influenza; TH is a co-investigator in a research project that receives funding from GlaxoSmithKline Inc; and MK has received research grant and/or contract funding from Roche, Merck Siemens and Gen-Probe, none of which relates to respiratory virus or influenza vaccine work.